Drugs / Gardisil-9
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07240220 | Feb 2026 → Aug 2028 expected | dysplasia of cervix | Indiana University | Not yet recruiting | No outcome recorded |
| — | NCT06411938 | Apr 2024 → May 2026 overdue | cervical cancer | Indiana University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gardisil-9 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07240220 ↗ |
| Known as | Gardasil-9 | “Up to an additional 2000 girls (daughters of participants in the Kenyan women arm) will be immunized against HPV using the 9-valent HPV vaccine (Gardasil-9).” NCT07240220 ↗ |
| Modality | Vaccine | “The 9 valent vaccine will be offered to 2000 adolescent girls.” NCT06411938 ↗ |